

PATENT
ATTORNEY DOCKET NO. 50026/012004

Certificate of Mailing: Date of Deposit: September 19, 2002

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Elaine Fabrizio

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

Applicant: Keiya Ozawa et al.

Art Unit: 1634

SEP 26 2

Serial No.: 09/905,591

Examiner:

TECH CENTER 10

Filed: July 13, 2001

Customer No.: 21559

Title: GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office Action on the merits.

Applicants hereby request that an initialed copy of the Form PTO-1449 submitted with the Information Disclosure Statement mailed on July 13, 2001 be returned with the next action.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 19 September 2002


James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559
PATENT TRADEMARK OFFICE



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Sheet 1 of 1

| | | | | | | |
|---|---|--|-----------------------------|----------------------------------|----------|---------------------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | Attorney Docket No. 50026/012004 | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | (37 C.F.R. §1.98(b)) | | Serial No. 09/905,591 | | |
| | | | | Applicant Keiya Ozawa et al. | | |
| | | | | Filing Date July 13, 2001 | | |
| | | | | Group 1634 | | |
| | | | | IDS Filed September 19, 2002 | | |
| U.S. PATENTS | | | | | | |
| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) |
| | | | | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
| | | | | | | |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | |
| | Chan et al., "A Murine Cytokine Fusion Toxin Specifically Targeting the Murine Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Receptor on Normal Committed Bone Marrow Progenitor Cells and GM-CSF-Dependent Tumor Cells," <i>Blood</i> 86:2732-2740 (1995). | | | | | |
| | Ito et al., "G-CSFR-Estrogen-R Fusion cDNA as a Novel Selective Amplifier Gene for Controllable Expansion of Transduced Hematopoietic Stem Cells," (Abstract 538) <i>Blood</i> 88:137A (1996). | | | | | |
| | Jackson et al., "Hormone-Conditional Transformation by Fusion Proteins of c-Abl and its Transforming Variants," <i>EMBO J</i> 12:2809-2819 (1993). | | | | | |
| | Nagata and Fukunaga, "Granulocyte Colony-Stimulating Factor and its Receptor," <i>Prog. Growth Factor Res.</i> , 3:131-141 (1991). | | | | | |
| | Ozawa et al., "Development of a Novel Selective Amplifier Gene for <i>In Vivo</i> Selective Expansion of Transduced Hematopoietic Stem Cells," (Abstract 161) <i>Experimental Hematology</i> 24:1053 (1996). | | | | | |
| | Williams and Park, "Hematopoietic Effects of a Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin-3 Fusion Protein," <i>Cancer</i> 67(Supplement):2705-2707 (1991). | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | | | | | | |